Fukaura H, Kent S C, Pietrusewicz M J, Khoury S J, Weiner H L, Hafler D A
Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
J Clin Invest. 1996 Jul 1;98(1):70-7. doi: 10.1172/JCI118779.
Oral administration of antigen is a long recognized method of inducing systemic immune tolerance. In animals with experimental autoimmune disease, a major mechanism of oral tolerance triggered by oral administration of antigen involves the induction of regulatory T cells that mediate active suppression by secreting the cytokine TGF-beta 1. Multiple sclerosis (MS) is a presumed T cell-mediated Th1 type autoimmune disease. Here, we investigated whether in MS patients oral myelin treatment, containing both myelin basic protein (MBP) and proteolipid protein (PLP), induced antigen specific MBP or PLP reactive T cells that either secreted IL4, TGF-beta1, or alternatively did Th1 type sensitization occur as measured by IFN-gamma secretion. Specifically, 4,860 short-term T cell lines were generated to either MBP, PLP, or tetanus toxoid (TT) from 34 relapsing-remitting MS patients: 17 orally treated with bovine myelin daily for a minimum of 2 yr as compared to 17 nontreated patients. We found a marked increase in the relative frequencies of both MBP and PLP specific TGF-beta1-secreting T cell lines in the myelin treated MS patients as compared to non-treated MS patients (MBP P < 0.001, PLP P < 0.003). In contrast, no change in the frequency of MBP or PLP specific IFN-gamma or TT specific TGF-beta1 secreting T cells were observed. These results suggest that the oral administration of antigens generates antigen specific TGF-beta1 secreting Th3 cells of presumed mucosal origin that represent a distinct lineage of T cells. Since antigen-specific TGF-beta1 secreting cells localize to the target organ and then suppress inflammation in the local microenvironment, oral tolerization with self antigens may provide a therapeutic approach for the treatment of cell-mediated autoimmune disease which does not depend upon knowledge of the antigen specificity of the original T cell clone triggering the autoimmune cascade.
口服抗原是一种长期以来被认可的诱导全身免疫耐受的方法。在患有实验性自身免疫性疾病的动物中,口服抗原引发的口服耐受的主要机制涉及诱导调节性T细胞,这些调节性T细胞通过分泌细胞因子转化生长因子β1(TGF-β1)介导主动抑制。多发性硬化症(MS)被认为是一种T细胞介导的Th1型自身免疫性疾病。在此,我们研究了在MS患者中,口服包含髓鞘碱性蛋白(MBP)和蛋白脂蛋白(PLP)的髓磷脂治疗是否会诱导分泌IL4、TGF-β1的抗原特异性MBP或PLP反应性T细胞,或者通过IFN-γ分泌来衡量是否发生Th1型致敏。具体而言,从34例复发缓解型MS患者中产生了4860个针对MBP、PLP或破伤风类毒素(TT)的短期T细胞系:17例患者每天口服牛髓磷脂至少2年,与17例未治疗的患者相比。我们发现,与未治疗的MS患者相比,接受髓磷脂治疗的MS患者中,MBP和PLP特异性分泌TGF-β1的T细胞系的相对频率显著增加(MBP P < 0.001,PLP P < 0.003)。相比之下,未观察到MBP或PLP特异性IFN-γ分泌T细胞或TT特异性TGF-β1分泌T细胞的频率发生变化。这些结果表明,口服抗原会产生推测为黏膜来源的分泌抗原特异性TGF-β1的Th3细胞,它们代表了一种独特的T细胞谱系。由于分泌抗原特异性TGF-β1的细胞定位于靶器官,然后在局部微环境中抑制炎症,用自身抗原进行口服耐受可能为治疗细胞介导的自身免疫性疾病提供一种治疗方法,这种方法不依赖于引发自身免疫级联反应的原始T细胞克隆的抗原特异性知识。